The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome

被引:0
作者
Bahar Artim-Esen
Reyhan Diz-Küçükkaya
Murat İnanç
机构
[1] Istanbul University,
[2] Istanbul Faculty of Medicine,undefined
[3] Department of Internal Medicine,undefined
[4] Division of Rheumatology,undefined
[5] Istanbul Bilim University Medical Faculty,undefined
[6] Department of Internal Medicine,undefined
[7] Division of Hematology,undefined
来源
Current Rheumatology Reports | 2015年 / 17卷
关键词
Thrombocytopenia; Antiphospholipid syndrome; Immune thrombocytopenia; Antiphospholipid antibody; Thrombotic thrombocytopenic purpura; Heparin-induced thrombocytopenia; HELLP; Pre-eclampsia;
D O I
暂无
中图分类号
学科分类号
摘要
The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.
引用
收藏
相关论文
共 261 条
[81]  
Strickland DK(2010)Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity Pathophysiol Haemost Thromb 37 104-107
[82]  
Laman JD(1995)EDTA-dependent pseudothrombocytopenia. Association with antiplatelet and antiphospholipid antibodies Am J Clin Pathol 103 103-63
[83]  
Claassen E(2010)Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study Blood 116 3058-22
[84]  
Noelle RJ(2012)B-cell directed therapies in antiphospholipid antibody syndrome—new directions based on murine and human data Autoimmun Rev 11 717-4
[85]  
Nakamura M(2010)Use of rituximab in the antiphospholipid syndrome Curr Rheumatol Rep 12 40-S82
[86]  
Tanaka Y(2013)B-cell depletion in immune thrombocytopenia Semin Hematol 50 S75-442
[87]  
Satoh T(2013)B cell deletion in immune thrombocytopenia reveals splenic long-lived plasma cells J Clin Invest 123 432-76
[88]  
Vlachoyiannopoulos PG(2010)Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases Clin Exp Rheumatol 28 468-71
[89]  
Mavragani CP(2013)A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome Arthritis Rheum 65 464-96
[90]  
Bourazopoulou E(2014)International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends Autoimmun Rev 13 685-90